143 related articles for article (PubMed ID: 38491392)
1. Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers.
Ma F; Li Y; Xiang C; Wang B; Lv J; Wei J; Qin Z; Pu Y; Li K; Teng H; Tan S; Feng J; Shang Z; Wang Y; Tian S; Du C; Han Y; Ding C
J Hematol Oncol; 2024 Mar; 17(1):11. PubMed ID: 38491392
[TBL] [Abstract][Full Text] [Related]
2. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
[TBL] [Abstract][Full Text] [Related]
3. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
4. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.
Li H; Miao Y; Zhong L; Feng S; Xu Y; Tang L; Wu C; Zhang X; Gu L; Diao H; Wang H; Wen Z; Yang M
Front Immunol; 2023; 14():1162032. PubMed ID: 37187751
[TBL] [Abstract][Full Text] [Related]
5. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
6. A multi-omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma.
Jin X; Liu L; Wu J; Jin X; Yu G; Jia L; Wang F; Shi M; Lu H; Liu J; Liu D; Yang J; Li H; Ni Y; Luo Q; Jia W; Wang W; Chen WL
Clin Transl Med; 2021 Sep; 11(9):e538. PubMed ID: 34586744
[TBL] [Abstract][Full Text] [Related]
7. Perioperative immunotherapy for esophageal squamous cell carcinoma.
Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
[TBL] [Abstract][Full Text] [Related]
8. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
[TBL] [Abstract][Full Text] [Related]
9. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
[TBL] [Abstract][Full Text] [Related]
10. Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma.
Zheng B; Li J; Zhang M; Zhang P; Deng W; Pu Y
Front Immunol; 2023; 14():1117658. PubMed ID: 36817484
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an autophagy-related gene signature for predicting prognosis in patients with esophageal squamous cell carcinoma.
Shi X; Li Y; Pan S; Liu X; Ke Y; Guo W; Wang Y; Ruan Q; Zhang X; Ma H
Sci Rep; 2022 Feb; 12(1):1960. PubMed ID: 35121801
[TBL] [Abstract][Full Text] [Related]
12. Mass Spectrometry for Biomarkers Discovery in Esophageal Squamous Cell Carcinoma.
Islam F; Gopalan V; Lam AK
Methods Mol Biol; 2020; 2129():259-268. PubMed ID: 32056183
[TBL] [Abstract][Full Text] [Related]
13. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.
Kashyap MK; Harsha HC; Renuse S; Pawar H; Sahasrabuddhe NA; Kim MS; Marimuthu A; Keerthikumar S; Muthusamy B; Kandasamy K; Subbannayya Y; Prasad TS; Mahmood R; Chaerkady R; Meltzer SJ; Kumar RV; Rustgi AK; Pandey A
Cancer Biol Ther; 2010 Oct; 10(8):796-810. PubMed ID: 20686364
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
15. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma.
Zhang D; Zhao F; Li J; Qin X; Li S; Niu R
Aging (Albany NY); 2023 Aug; 15(15):7811-7830. PubMed ID: 37561524
[TBL] [Abstract][Full Text] [Related]
16. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.
Kuo IY; Chang JM; Jiang SS; Chen CH; Chang IS; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
Int J Med Sci; 2014; 11(8):779-87. PubMed ID: 24936140
[TBL] [Abstract][Full Text] [Related]
17. Development of chemotherapeutics for unresectable advanced esophageal cancer.
Imazeki H; Kato K
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1083-1092. PubMed ID: 32820965
[TBL] [Abstract][Full Text] [Related]
18. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
Han D; Han Y; Guo W; Wei W; Yang S; Xiang J; Che J; Zhu L; Hang J; van den Ende T; van Laarhoven HWM; Li B; Ye Y; Li H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016720
[TBL] [Abstract][Full Text] [Related]
19. Identification of m6A/m5C-related lncRNA signature for prediction of prognosis and immunotherapy efficacy in esophageal squamous cell carcinoma.
Wang J; Ren H; Xu C; Yu B; Cai Y; Wang J; Ni X
Sci Rep; 2024 Apr; 14(1):8238. PubMed ID: 38589454
[TBL] [Abstract][Full Text] [Related]
20. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Iwabu J; Yamashita S; Takeshima H; Kishino T; Takahashi T; Oda I; Koyanagi K; Igaki H; Tachimori Y; Daiko H; Nakazato H; Nishiyama K; Lee YC; Hanazaki K; Ushijima T
Sci Rep; 2019 Sep; 9(1):13347. PubMed ID: 31527639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
